ClinicalTrials.gg
Not yet recruitingNCT06916130Updated Apr 8, 2025

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

A Phase 1 interventional study of AD-120A and AD-120 in Gastroesophageal Reflux Disease (GERD), sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Planned enrollment
27th of 52
48 · median 54
Started
2025
with 3 others
Phase 1
21 of 71
2 open now
Registered
61st of 71
by date
Lead sponsor
5 of 71
Addpharma Inc.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 in phase 1, and was the 61st registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.

Read the detailed description

The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-120 compared with AD-120A in healthy subjects.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit
  • Negative result from Serum Helicobacter pylori antibody at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Patients with trouble performing pH monitor catheter
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm-A

    Period 1 : Test Drug (AD-120), Period 2 : Reference Drug (AD-120A)

    Drug: AD-120A · Drug: AD-120

  • Experimental
    Arm-B

    Period 1 : Reference Drug (AD-120A), Period 2 : Test Drug (AD-120)

    Drug: AD-120A · Drug: AD-120

Interventions

  • DrugAD-120A

    Administered before the breakfast during 7 days, Oral, Tablet

    Also known as: Reference Drug

  • DrugAD-120

    Administered before the breakfast during 7 days, Oral, Tablet

    Also known as: Test drug

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ,ss)

    AUCτ,ss after 7days repeated administration of Omeprazole

    Time frame: AUCτ,ss: pre-dose to 24 hours of 1st administration versus pre-dose to 24 hours of repeated administration (7days)

  2. The time of peak concentration after single dose

    Tmax after 1days administration of Omeprazole

    Time frame: Tmax: from pre-dose to 24 hours of 1st administration

  3. Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring

    Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring for 24-hour interval after 7th dose

    Time frame: 24 hours before 1st administration to 24 hours after repeated administration (7days)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Sep 2025, 4 months later.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 4 months is close to that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 8, 2025
StartEst.
Apr 21, 2025
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06916130
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 21, 2025 (estimated)
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Apr 8, 2025

Study contacts

Hanna Yang
Contact
hnyang@addpharma.co.kr
+82-31-891-6918
Seung Hwan Lee, M.D., Ph.D.
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion